


=> d que 112

L9

STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 74

STEREO ATTRIBUTES: NONE

L11 1 SEA FILE=REGISTRY SSS FUL L9

L12 5 SEA FILE=HCAPLUS L11

=> fil reg

FILE 'REGISTRY' ENTERED AT 14:57:58 ON 19 MAY 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 MAY 2004 HIGHEST RN 683203-75-0

DICTIONARY FILE UPDATES: 18 MAY 2004 HIGHEST RN 683203-75-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:04:59 ON 19 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 May 2004 VOL 140 ISS 21
FILE LAST UPDATED: 18 May 2004 (20040518/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d ti rn l12 1-5

✓ L12 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Peptide composition for treatment of sexual dysfunction
RN 9068-52-4
RN 37213-49-3
RN 168482-23-3
RN 646031-08-5P
RN 646031-09-6P
RN 646031-10-9P
RN 646031-11-0P
RN 646031-12-1P
RN 646031-13-2P
RN 646031-14-3P
RN 646031-15-4P
RN 646031-16-5P
RN 646031-17-6P
RN 646031-18-7P
RN 646031-19-8P
RN 646031-20-1P
RN 58-22-0
RN 139755-83-2
RN **189691-06-3**
RN 143824-77-5

✓ L12 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
TI PT-141: a melanocortin agonist for the treatment of sexual dysfunction

RN 60-92-4
RN 37213-49-3D
RN **189691-06-3**

✓ L12 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Pharmaceutical compositions containing a peptide for treatment of sexual
dysfunction
RN **189691-06-3**
RN **189691-06-3D**
RN 8012-39-3

✓ L12 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Compositions and methods for treatment of sexual dysfunction
RN 4289-02-5
RN 31008-44-3
RN **189691-06-3**


X L12 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Biological and Conformational Examination of Stereochemical Modifications
Using the Template Melanotropin Peptide, Ac-Nle-c[Asp-His-Phe-Arg-Trp-Ala-
Lys]-NH₂, on Human Melanocortin Receptors
RN 581-05-5
RN 75921-69-6
RN 163560-08-5
RN **189691-06-3**
RN 189691-08-5
RN 189691-11-0
RN 189691-13-2
RN 189691-15-4
RN 60-92-4

=> d his 1

(FILE 'MEDLINE, HCAPLUS, WPIDS' ENTERED AT 14:32:33 ON 19 MAY 2004)
 L15 28 DUP REM L6 L12 L14 (7 DUPLICATES REMOVED)

=> d que 115

L1 196 SEA BLOOD C?/AU
 L2 114 SEA SHADIACK A?/AU
 L3 4983 SEA BERNSTEIN J?/AU
 L4 237 SEA HERBERT G?/AU
 L5 5505 SEA (L1 OR L2 OR L3 OR L4)
 L6 6 SEA L5 AND (CYCLIC? OR CIRCUL?) (3A) PEPTID?
 L7 134 SEA FILE=REGISTRY 'NLE'DH.RWK/SQSP
 L9 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 74

STEREO ATTRIBUTES: NONE

L11 1 SEA FILE=REGISTRY SSS FUL L9
 L12 5 SEA FILE=HCAPLUS L11
 L13 224 SEA FILE=HCAPLUS L7
 L14 24 SEA FILE=HCAPLUS L13 AND (CYCLIC? OR CIRCUL?) (3A) PEPTID?
 L15 28 DUP REM L6 L12 L14 (7 DUPLICATES REMOVED)

=> d ibib abs hitstr 115 1-28

L15 ANSWER 1 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
 ACCESSION NUMBER: 2004:41502 HCAPLUS
 DOCUMENT NUMBER: 140:105305
 TITLE: Peptide composition for treatment of sexual dysfunction
 INVENTOR(S): Sharma, Shubh D.; **Shadiack, Annette M.**;
 Yang, Wei; Rajpurohit, Ramesh
 PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
 SOURCE: PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005324	A2	20040115	WO 2003-US21417	20030709
WO 2004005324	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2002-394756P P 20020709
 OTHER SOURCE(S): MARPAT 140:105305
 AB Peptides for treatment of sexual dysfunction, including erectile dysfunction and female sexual dysfunction, and combination drugs and method of use thereof, including a peptide of the invention and one or more second sexual dysfunction pharmaceutical agents are disclosed.

L15 ANSWER 2 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2
 ACCESSION NUMBER: 2003:58220 HCAPLUS
 DOCUMENT NUMBER: 138:117676
 TITLE: Linear and **cyclic** melanocortin receptor-specific **peptides**, and therapeutic use
 INVENTOR(S): Sharma, Shubh D.; **Shadiack, Annette M.**;
 Yang, Wei; Rajpurohit, Ramesh
 PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
 SOURCE: PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006620	A2	20030123	WO 2002-US22196	20020711
WO 2003006620	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
 UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-304836P P 20010711

OTHER SOURCE(S): MARPAT 138:117676

AB Linear and **cyclic peptides** are provided which are specific to melanocortin receptors and which exhibit agonist, antagonist, or mixed agonist-antagonist activity. The peptides of the invention may be used to treat e.g. erectile dysfunction and eating disorders.

L15 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:133936 HCAPLUS

DOCUMENT NUMBER: 138:180744

TITLE: Compositions and methods for the diagnosis and treatment of psychogenic erectile dysfunction

INVENTOR(S): Mann, Morris; Mann, Maria A.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 8 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003036514	A1	20030220	US 2002-198793	20020718
			US 2001-312358P P	20010815

PRIORITY APPLN. INFO.:

AB The present invention is directed to a group of linear and **cyclic peptides** having the structures: Ac-Nle-Asp-His-D-Phe-Cl-Arg-Trp-Lys-NH₂; Ac-Nle-Asp-His-D-Phe-Cl-Arg-Trp-Lys-Gly-NH₂; Ac-Nle-Asp-His-D-Phe-Cl-Arg-Trp-Lys-Gly-Pro-NH₂; Ac-Ser-Tyr-Ser-Nle-Asp-His-D-Phe-Cl-Arg-Trp-Lys-NH₂; Ac-Tyr-Ser-Nle-Asp-His-D-Phe-Cl-Arg-Trp-Lys-NH₂; and Ac-Ser-Nle-Asp-His-D-Phe-Cl-Arg-Trp-Lys-NH₂. These peptides, when systemically administered to animals, will bring about a sexual response and are thus useful for the diagnosis and treatment of psychogenic sexual dysfunction in the male.

IT 499120-60-4 499120-62-6 499120-64-8



499120-66-0 499120-68-2 499120-70-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment of psychogenic erectile dysfunction)

RN 499120-60-4 HCAPLUS

CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)


D1 - C1




RN 499120-62-6 HCAPLUS
 CN Glycinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-ar-chloro-
 D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysyl- (9CI) (CA INDEX NAME)

PAGE 1-A

D1-C1



PAGE 1-B




RN 499120-64-8 HCAPLUS
 CN L-Prolinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-ar-
 chloro-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysylglycyl- (9CI) (CA
 INDEX NAME)

PAGE 1-A

D1-C1

PAGE 2-A



-Bu-n


-CO₂H

RN 499120-66-0 HCAPLUS
 CN L-Lysinamide, N-acetyl-L-seryl-L-tyrosyl-L-seryl-L-norleucyl-L- α -
 aspartyl-L-histidyl-ar-chloro-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI)
 (CA INDEX NAME)


PAGE 1-A



D1 Cl




PAGE 2-A



PAGE 2-B

- - OH

PAGE 2-A



PAGE 3-A





RN 499120-70-6 HCAPLUS
 CN L-Lysinamide, N-acetyl-L-seryl-L-norleucyl-L- α -aspartyl-L-histidyl-
 ar-chloro-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

PAGE 1-A



D1-C1




L15 ANSWER 4 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:236047 HCAPLUS
 DOCUMENT NUMBER: 139:79275
 TITLE: Structure-activity relationship of **cyclic peptide** penta-c[Asp-His6-DPhe7-Arg8-Trp9-Lys]-NH₂ at the human melanocortin-1 and -4 receptors: His6 substitution
 AUTHOR(S): Cheung, Adrian Wai-Hing; Danho, Waleed; Swistok, Joseph; Qi, Lida; Kurylko, Grazyna; Rowan, Karen; Yeon, Mitch; Franco, Lucia; Chu, Xin-Jie; Chen, Li; Yagaloff, Keith
 CORPORATE SOURCE: Roche Research Center, Hoffmann-La Roche Inc., Nutley, NJ, 07110, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(7), 1307-1311
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A series of MT-II related **cyclic peptides**, based on potent but non-selective hMC4R agonist (Penta-c[Asp-His6-DPhe7-Arg8-Trp9-Lys]-NH₂) was prepared in which His6 residue was systematically substituted. Two of the most interesting peptides identified in this study are Penta-c[Asp-5-ClAtc-DPhe-Arg-Trp-Lys]-NH₂ and Penta-c[Asp-5-ClAtc-DPhe-Cit-Trp-Lys]-NH₂ which are potent hMC4R agonists and are either inactive or weak partial agonists (not tested for their antagonist activities) in hMC1R, hMC3R and hMC5R agonist assays.


IT **121062-08-6**, MT II
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (structure-activity relationship of His6-substituted **cyclic**
peptides penta-c[Asp-His6-DPhe7-Arg8-Trp9-Lys]-NH₂ at the human
 melanocortin-1 and -4 receptors)
 RN 121062-08-6 HCAPLUS
 CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-
 phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:223119 HCAPLUS
 DOCUMENT NUMBER: 139:47377

TITLE: Molecular determinants of melanocortin 4 receptor
ligand binding and MC4/MC3 receptor selectivity
AUTHOR(S): Nickolls, Sarah A.; Cismowski, Mary I.; Wang,
Xiaochuan; Wolff, Meira; Conlon, Paul J.; Maki,
Richard A.
CORPORATE SOURCE: Neurocrine Biosciences Inc., San Diego, CA, USA
SOURCE: Journal of Pharmacology and Experimental Therapeutics
(2003), 304(3), 1217-1227
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: American Society for Pharmacology and Experimental
Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The mol. basis of ligand recognition by the melanocortin 4 receptor (MC4R)
has not been fully defined. In this study, we investigated the mol.
determinants of MC4R ligand binding, employing a large array of ligands,
using three approaches. First; mol. modeling of the receptor was used to
identify Phe284, in transmembrane (TM) 7, as a potential site of ligand
interaction. Mutation of Phe284 to alanine reduced binding affinity and
potency of peptides containing L-Phe by up to 71-fold but did not appreciably
affect binding of linear peptides containing D-Phe, consistent with a
hydrophobic interaction between the Phe7 of α -MSH and Phe284.
Second, we examined the effect of a naturally occurring mutation in TM3
(I137T) that is linked to obesity. This mutation decreased affinity and
potency of **cyclic**, rigid **peptides** but not more
flexible peptides, consistent with an indirect effect of the mutation on
the tertiary structure of the receptor. Third, we examined the residues
that support ligand selectivity for the MC4R over the MC3R. Mutation of
Ile125 (TM3) of the MC4R to the equivalent residue of the MC3R (phenylalanine)
selectively decreased affinity and potency of MC4R-selective ligands.
This effect was mirrored by the reciprocal MC3R mutation F157I. The
magnitude of this effect indicates that this locus is not of major
importance. However, it is considered that an isoleucine/phenylalanine
mutation may affect the orientation of Asp122, which has been identified
as a major determinant of ligand binding affinity. Thus, this study
provides further characterization of the MC4R binding pocket.
IT 121062-08-6, MTII 168482-23-3, SHU9119
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
BIOL (Biological study)
(mol. determinants of melanocortin 4 receptor ligand binding and
MC4/MC3 receptor selectivity)
RN 121062-08-6 HCAPLUS
CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-
phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 168482-23-3 HCAPLUS


CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-3-(2-naphthalenyl)-D-alanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:83841 HCAPLUS

DOCUMENT NUMBER: 138:379356

TITLE: Novel selective melanocortin 4 receptor antagonist induces food intake after peripheral administration

AUTHOR(S): Schioth, Helgi B.; Kask, Ants; Mutulis, Felixss; Muceniece, Ruta; Mutule, Ilga; Mutule, Ilze; Mandrika, Ilona; Wikberg, Jarl E. S.

CORPORATE SOURCE: Department of Neuroscience, Uppsala University, Uppsala, 751 24, Swed.

SOURCE: Biochemical and Biophysical Research Communications (2003), 301(2), 399-405

CODEN: BBRC A9; ISSN: 0006-291X

PUBLISHER: Elsevier Science
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The authors synthesized a new series of small cyclic MSH analogs and screened them for binding affinity at the four MSH binding melanocortin (MC) receptors. The authors identified a novel substance HS131, with about 20-fold higher affinity for the MC4 receptor than the MC3 receptor. This substance proved to be antagonist for all the four MC receptors in a cAMP assay. HS131 is a six amino acid long peptide, has a mol. weight below 1000, and has only two amino acids in common with the natural MSH peptides. HS131 potentially and dose dependently increased food intake after i.c.v. administration. Moreover, s.c. administration of HS131 (1.0 mg/kg) increased food intake, suggesting that HS131 may be able to pass the blood brain barrier. This **cyclic** low mol. weight **peptidomimetic** will enable studies of the functional role of the MC4 receptors by peripheral administration and it may be used as a template for further development of low mol. weight substances for the MC receptors.

IT **121062-08-6**, MTII **168482-23-3**, SHU9119

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)


(melanotropin analog binding by melanotropin receptor subtypes and identification of selective melanocortin 4 receptor antagonist inducing food intake after peripheral administration)

RN 121062-08-6 HCAPLUS


CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 168482-23-3 HCAPLUS

CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-3-(2-naphthalenyl)-D-alanyl-L-arginyl-L-tryptophyl-, (2→7)-lactam (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A





REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 7 OF 28 MEDLINE on STN DUPLICATE 3
 ACCESSION NUMBER: 2003319542 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 12851303
 TITLE: PT-141: a melanocortin agonist for the treatment of sexual dysfunction.
 AUTHOR: Molinoff P B; **Shadiack A M**; Earle D; Diamond L E; Quon C Y
 CORPORATE SOURCE: Palatin Technologies, Inc, Cranbury, New Jersey 08512, USA.
 SOURCE: Annals of the New York Academy of Sciences, (2003 Jun) 994 96-102.
 Journal code: 7506858. ISSN: 0077-8923.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200308
 ENTRY DATE: Entered STN: 20030710
 Last Updated on STN: 20030830
 Entered Medline: 20030829

AB PT-141, a synthetic peptide analogue of alpha-MSH, is an agonist at melanocortin receptors including the MC3R and MC4R, which are expressed primarily in the central nervous system. Administration of PT-141 to rats and nonhuman primates results in penile erections. Systemic administration of PT-141 to rats activates neurons in the hypothalamus as shown by an increase in c-Fos immunoreactivity. Neurons in the same region of the central nervous system take up pseudorabies virus injected into the corpus cavernosum of the rat penis. Administration of PT-141 to normal men and to patients with erectile dysfunction resulted in a rapid dose-dependent increase in erectile activity. The results suggest that PT-141 holds promise as a new treatment for sexual dysfunction.

L15 ANSWER 8 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:595493 HCAPLUS

DOCUMENT NUMBER: 137:145614

TITLE: Pharmaceutical compositions containing a peptide for treatment of sexual dysfunction

INVENTOR(S): Blood, Christine H.; Shadiack, Annette M.; Bernstein, Joanna K.; Herbert, Guy H.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S. Ser. No. 606,501.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2002107182	A1	20020808	US 2002-40547	20020104
US 6579968	B1	20030617	US 2000-606501	20000628
PRIORITY APPLN. INFO.:			US 1999-142346P P	19990629
			US 2000-194987P P	20000405
			US 2000-606501 A2	20000628

AB Comps. and methods are provided for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction. In one embodiment, a peptide-based composition including the peptide sequence Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH (I) is administered. Methods of administration include injection, oral, nasal and mucosal administration. I was dissolved in a 50 mM citrate, pH approx. 6.0, at a concentration of .825 mg per mL to obtain a nasal solution

Nasal

administration of I at a concentration of 25 µk/kg induced 100% penile erection in rats for 2 times in 30 min.

IT **189691-06-3 189691-06-3D**, salts

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL



(Biological study); USES (Uses)

(pharmaceutical comps. containing peptide for treatment of sexual dysfunction)

RN 189691-06-3 HCAPLUS



CN L-Lysine, N-acetyl-L-norleucyl-L-α-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, (2→7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189691-06-3 HCAPLUS
 CN L-Lysine, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 9 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:171949 HCAPLUS
 DOCUMENT NUMBER: 136:217052
 TITLE: Preparation of **cyclic peptides**
 having melanocortin-4 receptor (MC4-R) agonist
 activity
 INVENTOR(S): Chen, Li; Cheung, Adrian Wai-hing; Chu, Xin-jie;
 Danho, Waleed; Swistok, Joseph; Wang, Yao; Yagaloff,
 Keith Alan
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.
 SOURCE: PCT Int. Appl., 230 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018437	A2	20020307	WO 2001-EP9630	20010821
WO 2002018437	A3	20020606		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001084026	A5	20020313	AU 2001-84026	20010821
EP 1315750	A2	20030604	EP 2001-962958	20010821
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004507558	T2	20040311	JP 2002-523951	20010821
US 2002143141	A1	20021003	US 2001-939966	20010827
NO 2003000916	A	20030227	NO 2003-916	20030227
PRIORITY APPLN. INFO.:			US 2000-229184P	P 20000830
			WO 2001-EP9630	W 20010821
OTHER SOURCE(S):			MARPAT 136:217052	
GI				



AB The invention refers to peptides I [R1XYR12 is benzo or R1 is H, R2(NH)nCONH (R2 = alkyl, alkenyl, alkynyl; n = 0 or 1), or R2CONHCHR14CONH (R14 is alkyl); R12 is H; XY is C:C or CHCH; Q is (un)substituted methylene or phenylimino; R7 = O, NH; R8, R10 = H, Me; R9 is 3-indenylalkyl, 1- or 2-naphthyl; p = 0 or 1; m = 0-3; Z = CONH or S2], cyclized via disulfide or lactam bridges, having melanocortin-4 receptor (MC4-R) agonist activity and useful for treatment of obesity. Thus, BuCO-cyclo(Asp-Lys)-Asp-Apc-D-Phe-Arg-Trp-Lys-NH2 (Apc = 1-amino-4-phenyl-1-cyclohexanecarboxylic acid residue, Asp-Lys forms a lactam bridge) was prepared by the solid-phase method and showed EC50 = 9.2 and 654 nM, resp., in the MC-4 and MC-1 agonist assays.

IT **121062-08-6P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of **cyclic peptides** having melanocortin-4
receptor (MC4-R) agonist activity)

RN 121062-08-6 HCAPLUS


CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-
phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX
NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 117499-53-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)(preparation of **cyclic peptides** having melanocortin-4
receptor (MC4-R) agonist activity)

RN 117499-53-3 HCAPLUS

CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-
phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Chemical structure of the compound, showing a complex molecule with various functional groups and substituents, including a benzene ring, a thioether group, a thioamide group, a thioester group, and a thioether group.

PAGE 1-B

 CO_2H

L15 ANSWER 10 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:808505 HCAPLUS
DOCUMENT NUMBER: 138:19646
TITLE: Structure-activity studies of the melanocortin
peptides: Discovery of potent and selective affinity
antagonists for the hMC3 and hMC4 receptors
AUTHOR(S): Grieco, Paolo; Lavecchia, Antonio; Cai, Minying;
Trivedi, Devendra; Weinberg, David; MacNeil, Tanya;
Van der Ploeg, L. H. T.; Hruby, Victor J.
CORPORATE SOURCE: Department of Chemistry, University of Arizona,
Tucson, AZ, 85721, USA
SOURCE: Journal of Medicinal Chemistry (2002), 45(24),
5287-5294
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The authors have designed and synthesized several novel cyclic SHU9119 analogs (Ac-Nle4-[Asp5-His6-DNal(2')7-Arg8-Trp9-Lys10]-NH2) modified in position 6 with nonconventional amino acids. SHU9119 is a high affinity nonselective antagonist at hMC3R and hMC4R with potent agonist activity at hMC1R and hMC5R. The authors measured the binding affinity and agonist potency of the novel analogs at cloned hMC3R, hMC4R, and hMC5R receptors and identified several selective, high affinity hMC3R and hMC4R antagonists. Compound 4 containing Che substitution in position 6 is a high affinity hMC4R antagonist (IC50 = 0.48 nM) with 100-fold selectivity over hMC3R antagonist. Analog 7 with a Cpe substitution in position 6 is a high affinity hMC4R antagonist (IC50 = 0.51 nM) with a 200-fold selectivity vs. the hMC3R. Interestingly, analog 9 with an Acpc residue in position 6 is a high affinity hMC3R antagonist (IC50 = 2.5 nM) with 100-fold selectivity vs. the hMC4R antagonist based on its binding affinities. This compound represents the first cyclic lactam antagonist with high selectivity for the hMC3R vs. hMC4R. To understand the possible structural basis responsible for selectivity of these peptides at hMCR3 and hMCR4, the authors have carried out a mol. modeling study to examine the conformational properties of the **cyclic peptides** modified in position 6 with conformationally restricted amino acids.


IT **168482-23-3**, SHU9119 **168482-23-3D**, SHU9119, analogs
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (melanocortin peptides binding and antagonist activity at MC3 and MC4 receptors regulation by structure)

RN 168482-23-3 HCAPLUS


CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-3-(2-naphthalenyl)-D-alanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



PAGE 1-B





RN 168482-23-3 HCAPLUS

CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-3-(2-naphthalenyl)-D-alanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A





REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15/ ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2001:12284 HCAPLUS

DOCUMENT NUMBER: 134:76409

TITLE: Compositions and methods for treatment of sexual dysfunction

INVENTOR(S): Blood, Christine H.; Shadiack, Annette M.; Bernstein, Joanna K.; Herbert, Guy W.

PATENT ASSIGNEE(S): Palatin Technologies Inc., USA

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000224	A1	20010104	WO 2000-US18217	20000629
<p>W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p> <p>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG</p>				
US 6579968	B1	20030617	US 2000-606501	20000628
BR 2000012200	A	20020326	BR 2000-12200	20000629
EP 1196184	A1	20020417	EP 2000-950283	20000629
<p>R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,</p>				

IE, SI, LT, LV, FI, RO
JP 2003503357 T2 20030128
PRIORITY APPLN. INFO.:

JP 2001-505933 20000629
US 1999-142346P P 19990629
US 2000-194987P P 20000405
US 2000-606501 A 20000628
WO 2000-US18217 W 20000629

AB Compns. and methods are provided for the treatment of sexual dysfunctions in mammals, such as erectile dysfunction and female sexual dysfunction. In one embodiment, a peptide-based composition including the peptide sequence Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH is administered. Methods of administration include injection, oral, nasal and mucosal administration.

IT **189691-06-3**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(melanocortin analogs for treating sexual dysfunctions)


RN 189691-06-3 HCAPLUS

CN L-Lysine, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 12 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:719205 HCAPLUS

DOCUMENT NUMBER: 136:32071

TITLE: Selective, high affinity peptide antagonists of α -melanotropin action at human melanocortin receptor 4: Their synthesis and biological evaluation in vitro

AUTHOR(S): Bednarek, Maria A.; MacNeil, Tanya; Kalyani, Rubana N.; Tang, Rui; Van der Ploeg, Lex H. T.; Weinberg, David H.

CORPORATE SOURCE: Departments of Medicinal Chemistry and Obesity Research, Merck Research Laboratories, Rahway, NJ, 07065, USA

SOURCE: Journal of Medicinal Chemistry (2001), 44(22), 3665-3672

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Peptide Ac-Nle4-cyclo(5 β -10 ϵ)(Asp5-His6-D-(2')Nal7-Arg8-Trp9-Lys10)-NH₂, compound 1, a cyclic derivative of α -melanotropin, is a nonselective high affinity antagonist at human melanocortin receptors 3 and 4, and an agonist at melanocortin receptors 1 and 5. To differentiate between the physiol. functions of these receptors, antagonists with improved receptor selectivity are needed. In this study, analogs of compound 1 without Ac-Nle4 or His6 and/or the amino group of Asp5 were prepared and tested in binding assays and in functional assays on CHO cells expressing hMC3-5R. Several of these peptides were to be selective, high affinity hMC-4R antagonists. The most interesting was compound 10, named MBP10, cyclo(6 β -10 ϵ)(succinyl6-D-(2')Nal7-Arg8-Trp9-Lys10)-NH₂, an antagonist (IC₅₀ = 0.5 nM) with 125-fold selectivity over hMC-3R (and of >300-fold selectivity over MC-1RB). This compound had no agonist activity at hMC-3R or hMC-4R and only weak agonist activity at

hMC-5R. Examination of the sequences of these new peptides revealed that the D-(2')Nal7-Arg8-Trp9 segment of peptide 1 forms the "essential core" required for high affinity and high selectivity of analogs of peptide 1 at hMC-4R, but the "extended core", His6-D-(2')Nal7-Arg8-Trp9, is necessary for the maximum affinity for hMC-3R and hMC-5R.

IT **168482-23-3P 215858-99-4P**

RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)


(selective, high affinity peptide antagonists of α -melanotropin action at human melanocortin receptor 4: synthesis and biol. evaluation in vitro)

RN 168482-23-3 HCAPLUS


CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-3-(2-naphthalenyl)-D-alanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A




PAGE 1-B




RN 215858-99-4 HCAPLUS
 CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-3-(2-naphthalenyl)-L-alanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 13 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:692549 HCAPLUS

DOCUMENT NUMBER: 138:313897

TITLE: Highly selective **cyclic peptides**
 for human melanocortin-4 receptor (MC-4 R): design,
 synthesis, bioactive conformation, and pharmacological

evaluation as an anti-obesity agent

AUTHOR(S): Danho, Waleed; Swistok, Joseph; Cheung, Adrian; Chu, Xin-Jie; Wang, Yao; Chen, Li; Bartkovitz, David; Gore, Vijay; Qi, Lida; Fry, David; Greeley, David; Sun, Hongmao; Guenot, Jeanmarie; Franco, Lucia; Kurylko, Grazyna; Rumennik, Leonid; Yagaloff, Keith

CORPORATE SOURCE: Roche Research Center, Hoffmann-La Roche Inc., Nutley, NJ, 07110, USA

SOURCE: Peptides: The Wave of the Future, Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, CA, United States, June 9-14, 2001 (2001), 701-703. Editor(s): Lebl, Michal; Houghten, Richard A. American Peptide Society: San Diego, Calif.

DOCUMENT TYPE: CODEN: 69DBAL; ISBN: 0-9715560-0-8
Conference

LANGUAGE: English

AB The use of a selective melanocortin receptor-4 (MCR-4) **cyclic peptide** agonist as a pharmacol. tool in obesity and feeding studies was evaluated, and a pharmacophore model applicable to structure-based drug design was developed. Each of the four core amino acids of the MTII MCR-4 agonist was systematically replaced with conformationally constrained amino acids to evaluate the analogs in binding and cAMP assay at the human MC-1, -3, -4, and -5 receptors. The amino acid position occupied by His is the most critical position responsible for the selectivity of MC-4 against the other MC-receptors. A correlation was noted between high potency and the presence of a β turn at position corresponding to Asp-His-(D)Phe-Arg in the parent sequence.


IT **121062-08-6**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(design, synthesis and bioactive conformation of highly selective peptides for human melanocortin-4 receptor and pharmacol. evaluation as anti-obesity agents)


RN 121062-08-6 HCAPLUS

CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 14 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:509678 HCAPLUS

DOCUMENT NUMBER: 140:175300

TITLE: Synthesis and conformational studies of **cyclic peptides** with antagonist activity at melanocortin 3 and 4 receptors

AUTHOR(S): Grieco, Paolo; Novellino, Ettore; Lavecchia, Antonio; Weinberg, David; MacNeil, Tanya; Hruby, Victor J.

CORPORATE SOURCE: Dept. of Chemistry, University of Arizona, Tucson, AZ, USA

SOURCE: Peptides 2000, Proceedings of the European Peptide Symposium, 26th, Montpellier, France, Sept. 10-15, 2000 (2001), Meeting Date 2000, 643-644. Editor(s): Martinez, Jean; Fehrentz, Jean-Alain. Editions EDK: Paris, Fr.

CODEN: 69EDWK; ISBN: 2-84254-048-4

DOCUMENT TYPE: Conference

LANGUAGE: English

AB Analogs of SHU9119 (Ac-Nle-[Asp-His-DNal-Arg-Trp-Lys]-NH₂), i.e., peptides PG-913, PG-914, and PG-915, were synthesized in which His₆ residue was replaced by the unconventional amino acids Oic, Che and Aic, resp. The compound PG-913 was more selective toward the melanocortin 3 receptor (MC3R), whereas PG-915 had selectivity on the MC4R. Mol. modeling studies showed that the selectivity for MC3R over MC4R depends on steric properties of the residue in position 6 rather than on different overall conformational behavior.

IT 168482-23-3, SHU9119

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(synthesis and conformational studies of **cyclic peptides** with antagonist activity at melanocortin 3 and 4 receptors)


RN 168482-23-3 HCAPLUS

CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-3-(2-


naphthalenyl)-D-alanyl-L-arginyl-L-tryptophyl-, (2→7)-lactam (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



PAGE 1-B




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 15 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:707211 HCAPLUS
DOCUMENT NUMBER: 133:267160
TITLE: Preparation of **cyclic peptides** as melanocortin receptor ligands
INVENTOR(S): Mazur, Adam Wieslaw; Wang, Feng; Sheldon, Russell James; Ebetino, Frank Hal
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: PCT Int. Appl., 66 pp.

DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1 English
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000058361	A1	20001005	WO 2000-US7473	20000321
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
NZ 514141	A	20010928	NZ 2000-514141	20000321
EP 1165613	A1	20020102	EP 2000-919500	20000321
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009497	A	20020115	BR 2000-9497	20000321
TR 200102765	T2	20020521	TR 2001-200102765	20000321
JP 2002542159	T2	20021210	JP 2000-608653	20000321
AU 763510	B2	20030724	AU 2000-40179	20000321
AU 2000040179	A5	20001016		
RU 2213098	C2	20030927	RU 2001-128890	20000321
US 6613874	B1	20030902	US 2000-537789	20000329
ZA 2001007411	A	20020312	ZA 2001-7411	20010907
NO 2001004568	A	20011129	NO 2001-4568	20010920
US 2004023859	A1	20040205	US 2003-612104	20030702
PRIORITY APPLN. INFO.:			US 1999-126673P	P 19990329
			WO 2000-US7473	W 20000321
			US 2000-537789	A1 20000329
OTHER SOURCE(S):			MARPAT 133:267160	
GI				



I.

AB **Cyclic peptide** analogs I [m, n, q = 0-4; p = 0-5; X, E, Z = H, halo, OH, SH, NH₂, alkyl, cyano, nitro, aryl, heteroaryl, etc.; D = (un)substituted guanidino; R¹, R^{1'} = H, alkyl, aryl, heteroaryl or CR¹R^{1'} = cycloalkyl or aryl; G = optionally substituted bicyclic aryl or

heteroaryl; R, R11 = H, alkyl, alkene, alkyne, aryl, heteroaryl, cycloalkyl or R and R11 may join together to form a ring; W = covalent bond, CH₂, CO; M' = N, CH; B is an optionally substituted bridge moiety that links M' and W to form a ring and comprises a covalent bond or a ionic bond which may be substituted by ≤ 3 amino acid residues] were prepared for use in treating diseases that are mediated by the melanocortin (MC)-4 and/or the MC-3 receptor. Thus, Ac-a[**DYfRWGK**]-NH₂ (brackets denote amino acid points of cyclization) was prepared by the solid-phase method and evaluated for melanocortin functional activity and selectivity.

IT **117499-53-3P 213314-49-9P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of **cyclic peptides** as melanocortin receptor ligands)

RN 117499-53-3 HCAPLUS

CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


CO₂H


RN 213314-49-9 HCAPLUS

CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-tyrosyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:401591 HCAPLUS

DOCUMENT NUMBER: 133:38707

TITLE: Composition and method for regulation of body weight and associated conditions by administering proopiomelanocortin peptides or analogs thereof

INVENTOR(S): Brennan, Miles B.; Hochgeschwender, Ute

PATENT ASSIGNEE(S): Eleanor Roosevelt Institute, USA; Oklahoma Medical Research Foundation

SOURCE: PCT Int. Appl., 168 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033658	A1	20000615	WO 1999-US29337	19991209
W:				
AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6603058	B1	20030805	US 1999-374827	19990812
EP 1137340	A1	20011004	EP 1999-965208	19991209
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2003144174	A1	20030731	US 1999-458579	19991209

US 6716810 B1 20040406 US 1999-458580 19991209
 PRIORITY APPLN. INFO.: US 1998-111581P P 19981209
 US 1999-146299P P 19990729
 US 1999-146300P P 19990729
 US 1999-146301P P 19990729
 US 1999-146302P P 19990729
 US 1999-146303P P 19990729
 US 1999-146304P P 19990729
 US 1999-146305P P 19990729
 US 1999-146306P P 19990729
 US 1999-374827 A 19990812
 WO 1999-US29337 W 19991209

OTHER SOURCE(S): MARPAT 133:38707

AB Described are methods and compns. for regulating body weight and/or regulating the rate of weight gain or loss, and particularly, for treating or preventing obesity. Specifically, methods of administering varying levels of **circulating** proopiomelanocortin **peptides** or analogs thereof to an animal, alone or in combination with leptin or other body weight regulating agents are disclosed. Methods and compns. for treating a variety of disorders associated with or caused by undesirable body weight are also described. Also described are methods for identifying compds. useful for regulation of body weight and associated conditions. In particular,

methods

are disclosed for identification of compds. that preferentially bind to and/or activate peripheral melanocortin receptors and which minimize binding and/or activation of central melanocortin receptors. Also described is a genetically modified non-human animal model for studying the peripheral and central pathways of energy homeostasis. Also disclosed are methods of identifying compds. for regulating such pathways and a POMC mutant mouse. The compns. of the invention include food and pharmaceutical compns.

IT 168482-23-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(composition and method for regulation of body weight and associated conditions by


administering proopiomelanocortin peptides or analogs thereof)


RN 168482-23-3 HCAPLUS

CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-3-(2-naphthalenyl)-D-alanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A





REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 17 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:508309 HCAPLUS

DOCUMENT NUMBER: 131:252673

TITLE: Structure-function studies on the **cyclic peptide** MT-II, lactam derivative of α -melanotropin

AUTHOR(S): Bednarek, Maria A.; Silva, Maria V.; Arison, Byron; MacNeil, Tanya; Kalyani, Rubana N.; Huang, Ruey-Ruey C.; Weinberg, David H.

CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA

SOURCE: Peptides (New York) (1999), 20(3), 401-409
CODEN: PPTDD5; ISSN: 0196-9781

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The alanine-substituted and the retro, enantio, and retro-enantio analogs of MT-II, a potent agonist at melanocortin (MC) receptors, were prepared by solid-phase synthesis and evaluated for their ability to bind and activate human MC3, MC4, and MC5 receptors. Replacement of His with Ala resulted in [Ala6]-MT-II with affinity and agonist potency at human MC3, MC4, and MC5 receptors similar to MT-II. Substitution of Arg with Ala gave compound 100-fold less potent than MT-II, but replacement of Phe of Trp with Ala led to inactive compds. (at the micromolar concns.). The significant drop of potency of the retro, enantio, and retro-enantio analogs of MT-II, demonstrated a crucial role of side-chain topol., and to a lesser degree, of peptide backbone in interactions of MT-II with the melanocortin receptors. The NMR anal. of MT-II suggested involvement of Phe and Arg

residues in H-bonds stabilizing the bent conformations of the peptide backbone.


IT 121062-08-6, MT-II 168482-23-3, SHU9119
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
 (structure-function studies on **cyclic peptide**
 MT-II, lactam derivative of α -melanotropin)
 RN 121062-08-6 HCAPLUS
 CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 168482-23-3 HCAPLUS
 CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-3-(2-naphthalenyl)-D-alanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



PAGE 1-B



IT 245040-71-5P 245040-74-8P 245040-77-1P


RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)

(structure-function studies on **cyclic peptide**
MT-II, lactam derivative of α -melanotropin)

RN 245040-71-5 HCAPLUS

CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-L-alanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 245040-74-8 HCAPLUS

CN D-Lysinamide, N-acetyl-D-norleucyl-D- α -aspartyl-D-histidyl-L-phenylalanyl-D-arginyl-D-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 245040-77-1 HCAPLUS


CN D-Lysinamide, N-acetyl-D-norleucyl-D- α -aspartyl-D-histidyl-3-(2-naphthalenyl)-L-alanyl-D-arginyl-D-tryptophyl-, (2 \rightarrow 7)-lactam (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 18 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:192146 HCAPLUS

DOCUMENT NUMBER: 128:257693

TITLE: Preparation of peptides having potent antagonist and agonist bioactivities at melanocortin receptors

INVENTOR(S): Hadley, Mac E.; Hruby, Victor J.; Sharma, Shubh D.

PATENT ASSIGNEE(S): University of Arizona, Board of Regents, USA

SOURCE: U.S., 6 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5731408	A	19980324	US 1995-420972	19950410
US 6054556	A	20000425	US 1997-980238	19971128
PRIORITY APPLN. INFO.: GI			US 1995-420972	19950410

Ac-Nle-Asp-His-X-Arg-Trp-Lys-NH₂ I

AB **Cyclic lactam peptides I** [X = D-3-(2-naphthyl)alanine (D-2-Nal), D-p-iodophenylalanine [D-(p-I)Phe]] provided potent and specific antagonists of the two neural melanocortin receptors and of the peripheral receptor. In particular, peptide I (X = D-2-Nal) was a potent antagonist of the MC3 and MC4 receptors with partial agonist activity, and a full agonist of the MC1 and MC5 receptors. Peptide I [X = D-(p-I)Phe] was a potent antagonist of the MC3 and MC4 receptors with partial agonist activity. Both peptides I have antagonist activities in the classical frog skin bioassay for pigmentation at the MC1 receptor.

IT **168482-22-2P 168482-23-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(preparation of peptides having potent antagonist and agonist bioactivities at melanocortin receptors)


RN 168482-22-2 HCAPLUS

CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-4-iodo-D-phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A





REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 19 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1999:388818 HCAPLUS
 DOCUMENT NUMBER: 131:19304
 TITLE: Linear and cyclic analogs of alpha-MSH fragments with extraordinary potency
 INVENTOR(S): Hruby, Victor J.; Al-Obeidi, Fahad A.; Hadley, Mac E.
 PATENT ASSIGNEE(S): University Patents, Inc., USA
 SOURCE: Can., 42 pp.
 CODEN: CAXXA4
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 1340107	A1	19981027	CA 1988-578920	19880930
PRIORITY APPLN. INFO.:			CA 1988-578920	19880930

AB Cyclic alpha-MSH analogs are claimed for the manufacture of medicaments having melanotropic activity. Thus, Ac-[Nle⁴,D-Phe⁷,Lys¹⁰,Gly¹¹]-alpha-MSH⁴⁻¹³NH₂ was prepared by the solid-phase method. This linear peptide and its cyclized form showed prolonged melanocyte-stimulating activity in frog and lizard assays.


IT **117499-48-6P 117499-53-3P 117603-87-9P 121062-05-3P 121062-08-6P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of linear and cyclic analogs of alpha-MSH fragments with extraordinary potency)

RN 117499-48-6 HCAPLUS


CN L-Valinamide, N-acetyl-L-seryl-L-tyrosyl-L-seryl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysylglycyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




OH

RN 117499-53-3 HCAPLUS
 CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


CO₂H

RN 117603-87-9 HCAPLUS

CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





CO₂H

RN 121062-05-3 HCAPLUS

CN L-Valinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysylglycyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L15 ANSWER 20 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:507697 HCAPLUS

DOCUMENT NUMBER: 129:245475

TITLE: Synthesis of **cyclic α -MSH peptides**

AUTHOR(S): Schaaper, Wim M. M.; Adan, Roger A. H.; Posthuma, Truus A.; Oosterom, Julia; Gispen, Willem-Hendrik; Meloen, Rob H.

CORPORATE SOURCE: ID-DLO, Institute for Animal Science and Health, Lelystad, 8200 AB, Neth.

SOURCE: Letters in Peptide Science (1998), 5(2-3), 205-208
CODEN: LPSCEM; ISSN: 0929-5666

PUBLISHER: Kluwer Academic Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Cyclic analogs of α -MSH(1-13) and of α -MSH(4-10) have been synthesized. The peptides were synthesized using Fmoc chemical, and improvements in the cyclization step were made. For example, side chains of Asp5 and Lys10 in the deprotected peptide were coupled in DMF to form a cyclic lactam, using an excess of PyBOP reagent and DIEA as a base. The cyclization reaction was completed within 1 h and was almost quant. A cyclic analog of α -MSH, containing a disulfide bridge, was also synthesized. The peptides were tested for their selectivity for the rat MC4 receptor. Substitution of Phe7 of α -MSH, and cyclization of the peptide dramatically influenced the selectivity for the rMC4 receptor.

IT 168482-23-3P, MBX 36 213314-48-8P, MBJ 07
213314-49-9P, MBX 37

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and biol. activity of **cyclic α -MSH peptides**)


RN 168482-23-3 HCAPLUS

CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-3-(2-naphthalenyl)-D-alanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI)


(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



PAGE 1-B




RN 213314-48-8 HCAPLUS


CN L-Valinamide, N-acetyl-L-seryl-L-tyrosyl-L-seryl-L-norleucyl-L-α-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysylglycyl-L-prolyl-, (5→10)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C




PAGE 2-B




RN 213314-49-9 HCAPLUS
 CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-tyrosyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 21 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:34211 HCAPLUS

DOCUMENT NUMBER: 128:190087

TITLE: Octanol-water partition of nonzwitterionic peptides: predictive power of a molecular size-based model

AUTHOR(S): Buchwald, Peter; Bodor, Nicholas

CORPORATE SOURCE: Center for Drug Discovery, University of Florida, Health Science Center, Gainesville, FL, 32610-0497, USA

SOURCE: Proteins: Structure, Function, and Genetics (1998), 30(1), 86-99

CODEN: PSFGEY; ISSN: 0887-3585

PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A remarkably simple, mol. size-based model developed to predict octanol-water partition coeffs. for organic compds. is tested on a set of 188 neutral peptides with available exptl. partition data. Despite using only two parameters, it gives a promising correlation ($r^2 = 0.914$; $\sigma = 0.455$, $F = 1978.0$), and predictions are in a realistic range even for larger peptides (cyclosporin, melanotan, sandostatin) where common, overparametrized fragment methods become quite unreliable. Ion-pair partitioning and the extraction constant formalism is briefly reviewed to describe the sigmoidal lipophilicity profile of ionizable, nonzwitterionic peptides. It seems possible to extend the present model to estimate apparent partition coeffs. measured around neutral pH and physiol. conditions for monoionic peptides; however, as no standard conditions are yet defined and only relatively small number of exptl. data are available, the situation here is more complex.

IT 121062-08-6, Melanotan II

RL: PRP (Properties)

(octanol-water partition of nonzwitterionic peptides and predictive power of mol. size-based model)


RN 121062-08-6 HCAPLUS
 CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 22 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1997:735794 HCAPLUS
 DOCUMENT NUMBER: 127:346663
 TITLE: Preparation and biological activity of cyclic bridged α -MSH analogs
 INVENTOR(S): Hadley, Mac E.; Hruby, Victor J.; Sharma, Shubh D.
 PATENT ASSIGNEE(S): Competitive Technologies, Inc., USA
 SOURCE: U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 199,775, abandoned.

DOCUMENT TYPE: CODEN: USXXAM
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 2 English
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5683981	A	19971104	US 1995-470343	19950606
US 5674839	A	19971007	US 1994-349902	19941206
US 5714576	A	19980203	US 1997-826676	19970407
PRIORITY APPLN. INFO.:			US 1987-53229	B2 19870522
			US 1988-212807	B1 19880629
			US 1990-611456	B2 19901113
			US 1992-938781	B1 19920831
			US 1994-199775	B2 19940222
			US 1992-916767	B1 19920717
			US 1994-349902	A3 19941206

GI




- AB Novel cyclic bridged α -MSH analogs I and II (AA5, AA10, AA11 = L- or D-amino acid containing ω -amino or carboxyl group in the side chain; Xxx = 1-5 α -amino acid residues, each of which may be of L- or D-configuration, or linear or branched spacer chain containing terminal amino and/or carboxy groups; R1, R2 designates α -MSH1-13NH2, α -MSH1-12NH2, α -MSH1-11NH2, α -MSH4-13NH2, α -MSH4-10NH2) are described herein. With the described analogs, when administered in pharmaceutical compns., it is now possible to achieve normalization of hypopigmentation dysfunctions and to achieve darkening of the skin in the total absence of sun or UV light irradiation. Thus, **cyclic peptide** III was prepared by standard solid-phase methods and displayed α -MSH relative potencies of 100 in a frog skin assay and 5 in a lizard skin assay.
- IT 198267-22-0P, SHU 9020 198267-23-1P, SHU 9021
 198267-25-3P, SHU 9018
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and biol. activity of cyclic bridged α -MSH analogs)
- RN 198267-22-0 HCAPLUS
- CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-


phenylalanyl-L-arginyl-L-tryptophyl-N6-(L-arginyl-L-arginyl)-,
(2→7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 198267-23-1 HCAPLUS
CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-N6-(L-arginyl-L-lysyl)-,
(2→7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 198267-25-3 HCAPLUS


CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-N6-(L-lysyl-L-arginyl)-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L15 ANSWER 23 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:483379 HCAPLUS

DOCUMENT NUMBER: 127:117483

TITLE: β -Methylation of the Phe7 and Trp9 melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biological activity

AUTHOR(S): Haskell-Luevano, Carrie; Toth, Kate; Boteju, Lakmal; Job, Constatin; de Castrucci, Ana Maria; Hadley, Mac E.; Hruby, Victor J.

CORPORATE SOURCE: Departments of Chemistry and Anatomy, University of

SOURCE: Arizona, Tucson, AZ, 85721, USA
 Journal of Medicinal Chemistry (1997), 40(17),
 2740-2749
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Topog. modified melanotropin side chain pharmacophore residues Phe7 and Trp9 in a **cyclic peptide** template (Ac-Nle4-c[Asp-His-Xaa7-Arg-Yaa9-Lys]-NH2) and Phe7 in a linear peptide template (Ac-Ser-Tyr-Ser-Nle4-Glu-His-Xaa7-Arg-Trp-Gly-Lys-Pro-Val-NH2) result in differences in potency and prolonged biol. activity in the frog and lizard skin bioassays. These topog. modifications included the four isomers of β -methylphenylalanine (β -MePhe)7 and β -methyltryptophan (β -MeTrp)9 and the two isomers of 1,2,3,4-tetrahydro- β -carboline (Tca).9. Modifications in the cyclic template resulted in up to a 1000-fold difference in potency for the β -MePhe7 stereoisomeric peptides; up to a 476-fold difference in potency resulted for the β -MeTrp9 peptides, and about a 50-fold difference between the Tca9-containing peptides. Up to a 40-fold difference in potency resulted for the β -MePhe7 stereoisomeric peptides using the linear template in these assays. The relative potency ranking for modifications in the cyclic template of β -MePhe7 were 2R,3S > 2S,3S = 2S,3R > 2R,3R in the frog assay and 2S,3R > 2R,3S > 2S,3S > 2R,3R in the lizard assay. The relative potencies for modifications in the cyclic template of β -MeTrp9 were 2R,3S > 2R,3R > 2S,3S » 2S,3R in the frog assay and 2S,3S = 2R,3R > 2R,3S > 2S,3R in the lizard assay. The relative potencies for modifications in the cyclic template of Tca9 were DTca > LTca in both assays. Significant differences in prolonged (residual) activities were also observed for these modified peptides and were dependent upon stereochem. of the β -Me amino acid, peptide template, and bioassay system. Furthermore, comparisons of β -MeTrp9 stereoisomeric peptides on the frog, lizard, and human MC1 receptors suggest that structure-activity relationships on both the classical frog and lizard skin bioassays do not necessarily predict corresponding SAR profiles for the human melanocortin receptors, indicating a remarkable species specificity of the MC1 receptor requirements.



IT 121062-08-6 166255-31-8 166255-32-9
 166255-33-0 166255-34-1 169056-23-9
 192646-24-5 192646-25-6 192646-26-7
 192646-27-8 192646-28-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (β -methylation of the Phe7 and Trp9 melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biol. activity)

RN 121062-08-6 HCAPLUS

CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, (2-7)-lactam (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 166255-31-8 HCAPLUS
 CN L-Lysinamide, N-acetyl-L-norleucyl-L-α-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-(βS)-β-methyl-L-tryptophyl-, (2→7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 166255-32-9 HCAPLUS


CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-(β S)- β -methyl-D-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 166255-33-0 HCAPLUS


CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-(β R)- β -methyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 166255-34-1 HCAPLUS
 CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-(β R)- β -methyl-D-tryptophyl-,
 (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 169056-23-9 HCAPLUS


CN L-Lysinamide, N-acetyl-L-norleucyl-L-α-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-D-tryptophyl-, (2→7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 192646-24-5 HCAPLUS

L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.





PAGE 1-B





RN
CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-(β S)-
 β -methyl-L-phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam
(9CI) (CA INDEX NAME)

Search completed by David Schreiber x22526



RN 192646-26-7 HCAPLUS
 CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-(β R)-
 β -methyl-L-phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam
 (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 192646-27-8 HCAPLUS

CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-(β S)- β -methyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam
(9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 192646-28-9 HCAPLUS

CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-(β R)- β -methyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L15 ANSWER 24 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN


ACCESSION NUMBER: 1997:310073 HCAPLUS

DOCUMENT NUMBER: 126:325679

TITLE:  Biological and Conformational Examination of Stereochemical Modifications Using the Template Melanotropin Peptide, Ac-Nle-c[Asp-His-Phe-Arg-Trp-Ala-Lys]-NH₂, on Human Melanocortin Receptors

AUTHOR(S): Haskell-Luevano, Carrie; Nikiforovich, Gregory; Sharma, Shubh D.; Yang, Ying-Kui; Dickinson, Chris; Hruby, Victor J.; Gantz, Ira

CORPORATE SOURCE: Departments of Internal Medicine Pediatrics and Surgery, University of Michigan Medical Center, Ann Arbor, MI, 48109, USA

SOURCE:  Journal of Medicinal Chemistry (1997), 40(11), 1738-1748
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Examination of conformationally constrained melanotropin peptides (Ac-Nle4-c[Asp5-His-Phe7-Arg-Trp9-Ala-Lys]-NH2) on four human melanotropin receptors (hMC1R, hMC3R, hMC4R, and hMC5R) resulted in identifying the importance of ligand stereochem. at positions 5, 7, and 9 for agonist binding affinity and receptor selectivity. A trend in ligand structure-activity relationships emerged for these peptides, with the hMC1R and hMC4R possessing similar tendencies, as did the hMC3R and hMC5R. α -MSH (Ac-Ser-Tyr-Ser-Met4-Glu-His-Phe7-Arg-Trp-Gly-Lys-Pro-Val-NH2), NDP-MSH (Ac-Ser-Tyr-Ser-Nle4-Glu-His-d-Phe7-Arg-Trp-Gly-Lys-Pro-Val-NH2) and MTII (Ac-Nle4-c[Asp5, d-Phe7, Lys10]-NH2) were also examined at each of these melanocortin receptors. Interestingly, the linear NDP-MSH possessed greater binding affinity for the hMC3R and hMC5R than did the cyclic analog MTII. The peptide Ac-Nle-c[Asp-His-Phe-Arg-D-Trp9-Ala-Lys]-NH2 demonstrated the greatest differentiation in binding affinity between the hMC1R and hMC4R (78-fold). Analog Ac-Nle-c[Asp-His-Phe7-Arg-Trp-Ala-Lys]-NH2 resulted in micromolar binding affinity (or greater) at the hMC3R and hMC5R, demonstrating the importance of D-Phe7 for ligand binding potency at these receptors. Ac-c[Asp-His-Phe-Arg-Trp-Ala-Lys]-NH2 resulted in loss of binding affinity at the hMC5R, implicating the importance of Nle4 (or a hydrophobic residue in this position) for binding to this receptor. Ac-Nle-c[D-Asp5-His-Phe-Arg-Trp-Ala-Lys]-NH2 was unable to competitively displace [125I]NDP-MSH binding at micromolar concns. on the hMC3R and hMC5R, suggesting the importance of chirality of Asp5 either for ligand-receptor interactions or for orientation of the side chain lactam bridge and the structural integrity of the peptide conformation. Energy calcns. performed for these peptides resulted in the identification of a low-energy ligand conformer family that is common to all the ligands. The differences in ligand binding affinities observed in this study are postulated to be a result of different ligand-receptor complexed interactions and not solely to the ligand structure.


IT **189691-06-3**
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
 (biol. and conformational examination of stereochem. modifications using a template melanotropin peptide on human melanocortin receptors)


RN 189691-06-3 HCAPLUS

CN L-Lysine, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






(α -MSH analog binding and characterization of D117A and H260A

Q P 187. A 1463


mutations in melanocortin 1 receptor)
 RN 188981-70-6 HCAPLUS
 CN L-Lysine, L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-
 arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 188981-71-7 HCAPLUS
 CN L-Lysine, L-norleucyl-L- α -aspartyl-L-histidyl-3-(2-naphthalenyl)-D-
 alanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L15 ANSWER 26 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:250787 HCAPLUS

DOCUMENT NUMBER: 124:279637

TITLE: Evaluation of Melanotan-II, a superpotent
cyclic melanotropic peptide in pilot
phase-I clinical study

AUTHOR(S): Dorr, Robert T.; Lines, Ruskin; Levine, Norman;
Brooks, Christine; Xiang, Li; Hruby, Victor J.;
Hadley, Mac E.

CORPORATE SOURCE: Coll. Med., Univ. Arizona, Tucson, AZ, USA
SOURCE: Life Sciences (1996), 58(20), 1777-84
CODEN: LIFSAK; ISSN: 0024-3205
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A pilot phase I study was conducted with a cyclic heptapeptide analog of α -MSH. The lactam-bridged mol., called Melanotan-II (MT-II), has the structure Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10 α -MSH4-10-NH2 and has superpotent melanotropic activity in vitro. A single-blind, alternating day (saline or MT-II), placebo-controlled trial was conducted in 3 normal male volunteers at the starting dose of 0.01 mg/kg of MT-II. S.c. injections of MT-II or saline were given daily (Monday-Friday) for 2 consecutive weeks. Two subjects were escalated by 0.005 mg/kg increments to 0.03 mg/kg and one to 0.025 mg/kg. The 0.03 mg/kg dose produced Grade II somnolence and fatigue in one of two subjects (WHO stds.). Mild nausea, not requiring antiemetic treatment, was reported at most MT-II dose levels. A stretching and yawning complex appeared to correlate with the onset of spontaneous, penile erections which were intermittently experienced for 1-5 h after MT-II dosing, depending on the MT-II dose. Two subjects had increased pigmentation in the face, upper body and buttock as measured by quant. reflectance and by visual perception 1 wk after MT-II dosing ended. These results demonstrate that MT-II has tanning activity in humans given only 5 low doses every other day by s.c. injection. The recommended single MT-II dose for future Phase I studies is 0.025 mg/kg/day.

IT 121062-08-6, Melanotan-II


RL: ADV (Adverse effect, including toxicity); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(tanning activity and side effects in clin. study of Melanotan-II, a superpotent **cyclic** melanotropic **peptide**, in men)


RN 121062-08-6 HCAPLUS

CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L15 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1993:552245 HCAPLUS

DOCUMENT NUMBER: 119:152245

TITLE: A conformational study of two **cyclic peptide** analogs of α -MSH

AUTHOR(S): Forsyth, George; Branch, Sarah; Moss, Stephen; Notarianni, Lidia; Osguthorpe, David; Pouton, Colin
 CORPORATE SOURCE: Sch. Pharm. Pharmacol., Univ. Bath, Bath, BA2 7AY, UK
 SOURCE: Annals of the New York Academy of Sciences (1993), 680(Melanotropic Peptides), 517-19
 CODEN: ANYAA9; ISSN: 0077-8923

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Lowest energy conformations were determined for 2 **cyclic peptide** analogs of α -MSH by utilizing mol. dynamic simulations. Such studies have implications in the mol. modeling and computer-assisted design of new analogs.



IT 121062-08-6

RL: PRP (Properties)
 (conformation of)

RN 121062-08-6 HCAPLUS

CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 28 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1989:614935 HCAPLUS

DOCUMENT NUMBER: 111:214935

TITLE: Potent and prolonged-acting cyclic lactam analogs of α -melanotropin: design based on molecular dynamics

AUTHOR(S): Al-Obeidi, Fahad; Castrucci, Ana M. de L.; Hadley, Mac E.; Hruby, Victor J.

CORPORATE SOURCE: Dep. Chem., Univ. Arizona, Tucson, AZ, 85721, USA

SOURCE: Journal of Medicinal Chemistry (1989), 32(12), 2555-61


CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 111:214935

GI



AB Cyclic lactam fragment analogs of α -melanotropin (α -MSH) I (X = Glu, Asp; X¹ = Lys, Orn, Dab, Dpr; R = NH₂, Gly-Pro-Val-NH₂; Dab = 2,4-diaminobutyric acid, Dcpr = 2,3-diaminopropionic acid) were prepared. Formation of the lactam bridge between the side-chain groups X and X¹ was performed either in solution or on a solid-phase support. The **cyclic peptides** were bioassayed for their melanotropic potency using standard frog (*Rana pipiens*) and lizard (*Anolis carolinensis*) skin bioassays. Cyclic melanotropins with 23-membered rings exhibited 100-fold higher melanotropic potency than α -MSH, with selectivity for the lizard melanocyte receptors over the frog melanocyte receptors. Increasing or decreasing the ring size of these cyclic melanotropins diminishes the biol. potency. The 23 and 24-membered ring analogs showed prolonged (residual) biol. activities in both biol. assays, but the smaller ring systems did not. These results provide new insights into the structural and conformational requirements of α -MSH and its analogs at two different types of pigment cell (melanocyte) receptors.

IT 121062-05-3


RL: RCT (Reactant); RACT (Reactant or reagent)
(intramol. lactamization of)


RN 121062-05-3 HCAPLUS

CN L-Valinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysylglycyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






IT	117499-53-3P
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and intramol. lactamization of)
RN	117499-53-3 HCAPLUS
CN	L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D- phenylalanyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

CO₂H

IT 121062-08-6P 122235-72-7P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and melanotropic activity of)

RN 121062-08-6 HCAPLUS


CN L-Lysinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, (2 \rightarrow 7)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 122235-72-7 HCAPLUS
 CN L-Valinamide, N-acetyl-L-norleucyl-L- α -aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysylglycyl-L-prolyl-, cyclic (2 \rightarrow 7)-peptide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

